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Abstract
Background: The survival benefit of non-curative gastric resection for patients with stage IV gastric cancer is still
unclear.
Methods: Of the patients who underwent open abdominal surgery that was preoperatively intended to be a
radical excision procedure for gastric cancer, 72 were diagnosed with stage IV during the operation. At this
institution, non-curative gastric resection is performed whenever possible.
Results: Non-curative gastric resection was performed in 44 of the 72 patients. According to the survival analysis,
the median survival times in the gastric resection and no-resection groups were 1.9 and 0.9 years, respectively
(log-rank test, p = 0.014). Based on the multivariate analysis, we selected gastric resection (hazard ratio [HR] = 0.309;
95 % confidence interval [CI] = 0.152–0.615) and postoperative chemotherapy (HR = 0.136; 95 % CI = 0.056–0.353) as
independent factors associated with overall survival (OS). In the subgroup analyses of OS, the factors that were
associated with gastric resection having no survival benefit were the existence of distant lymph node or liver
metastasis (p = 0.527) and the lack of postoperative chemotherapy (p = 0.589).
Conclusions: For patients who have distant lymph node or liver metastasis and those who will not undergo
postoperative chemotherapy, non-curative gastric resection has no survival benefit.
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Background
The prognosis of stage IV gastric cancer is poor, with an
expected survival period of 3–5 months without treat-
ment [1]. The treatment strategies for patients with stage
IV gastric cancer mainly consist of chemotherapy, pallia-
tive surgery, and symptomatic treatment. Although sys-
temic chemotherapy has been reported to extend the
overall survival (OS) of patients with stage IV gastric
cancer [2], the impact of non-curative gastric resection
as palliative surgery is still unknown. Meanwhile, des-
pite improvement in preoperative examinations, the
diagnosis of stage IV gastric cancer is occasionally
made only after laparoscopic or open exploration. In
these cases, surgeons have to make an intraoperative
decision as to whether or not they perform a non-
curative gastric resection. In this study, we investigated
the impact and optimal indication of non-curative gastric




We examined all 1086 patients who underwent open ab-
dominal surgery for gastric cancer between July 2004
and June 2014 at Asahi General Hospital, Chiba, Japan.
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Among these patients, 72 (6.6 %) were diagnosed with
stage IV gastric cancer after open exploration that was
preoperatively intended to be a radical excision procedure
(R0 surgery). The objective of this study was to examine
these 72 patients. Cases of emergency surgery for bleeding
or perforation were excluded from this study.
Strategies for stage IV gastric cancer diagnosed during
the operation
When stage IV gastric cancer was diagnosed during the
operation, in principle, we removed the primary lesion
(total gastrectomy or gastric resection) as a volume re-
duction measure. When the tumor showed strong inva-
sion to other organs such as the pancreas, esophagus, or
duodenum, we did not perform the gastric resection,
and a gastrojejunostomy was performed as necessary for
the patients with a preoperative gastric obstruction. In
principle, we initiated chemotherapy as soon as possible
after surgery regardless of whether gastric resection was
performed. Chemotherapy was not administered to pa-
tients who refused or had general health issues that pre-
cluded chemotherapy.
Methods
These data were retrospectively analyzed based on pa-
tients’ medical records. The histological and pathological
findings were described according to the International
Union against Cancer (UICC) 7th edition of the tumor-
node-metastasis (TNM) classification. The 72 patients
were classified into two groups: patients who underwent
a non-curative gastric resection (gastric resection group)
and those who did not (no-resection group). We com-
pared the baseline characteristics between the two
groups. This study received a priori approval from the
institutional review committee.
Statistical analysis
The data are expressed as the median (range). Univariate
and multivariate analyses for survival were performed. We
analyzed the OS of all patients, and the subgroup analyses
examined the optimal indications for non-curative gastric
resection. The differences in surgical outcomes between
the resection and non-resection groups were evaluated
using Student’s t tests and chi-squared tests. A Cox pro-
portional hazard model based on the uni- and multivariate
analyses was used to assess the independent factors affect-
ing OS. The survival analysis was calculated using a log-
rank test. All statistical analyses were performed using the
StatView software package (SAS Institute, Cary, NC), and
differences with p < 0.05 were considered significant.
Results
The baseline characteristics of all 72 patients are shown
in Table 1. The median age was 68 years (range 22–87),
and this study included 50 male and 22 female patients.
The median follow-up period was 1.0 year (0.0–
5.0 years). The non-curative factors that resulted in the
diagnosis of stage IV cancer were peritoneal metastasis
(P+) in 38 patients, positive peritoneal cytology (CY+) in
38, distant lymph node metastasis (LN+) in 11, and liver
metastasis (H+) in 4. Postoperative chemotherapy was
administered to 56 patients (77.8 %). A TS-1® (combin-
ation capsules of tegafur, gimeracil, and oteracil potas-
sium, Taiho Pharmaceutical Co. Ltd, Japan) based regimen
was the most commonly used first line chemotherapy
(TS-1: n = 32 [57.1 %], TS1 + cisplatin: n = 12 [21.4 %]),
followed by irinotecan + CDDP in 5 patients (8.9 %), pacli-
taxel in 4 patients (7.1 %), and other forms in 3 patients.
Among the 72 patients who were diagnosed with stage
IV gastric cancer during the operation, 44 received a
non-curative gastric resection as a palliative surgery (14
gastrectomy and 30 total gastrostomy), 14 received a
gastrojejunostomy for bypass surgery, and 14 patients
received only a laparotomy. The reason precluding the
gastric resection was invasion to the pancreas in 19 pa-
tients, to the esophagus in 4 patients, to the duodenum
in 2 patients, and other reasons in 3 patients. Table 1
presents the comparison of the baseline characteristics
between the gastric resection (n = 44) and no-resection
groups (n = 28). There were no statistically significant
differences in patient’s age, ASA-physical status, and per-
formance status between the groups. In the gastric re-
section group, the operation time was longer and the
estimated amount of bleeding was much higher than in
the non-resection group (both p < 0.01). The complica-
tion rate (≥Clavian-Dindo class II) was higher in the
gastric resection group (p = 0.036), and one patient died
of anastomotic leakage of the transverse colon 16 days
postoperatively. The percentage of patients who received
chemotherapy was 79.5 % in the gastric resection group
and 75.0 % in the non-resection group, and this was not
significantly different (p = 0.651).
In the survival analysis, the median survival time
(MST) in the resection and non-resection groups were
1.9 and 0.9 years, respectively (p = 0.014) (Fig. 1). We
utilized a Cox proportional hazard model based on the
uni- and multivariate analyses to determine the inde-
pendent factors affecting OS (Table 2). In the univariate
analysis, we found that tubular adenocarcinoma, gastric
resection, and postoperative chemotherapy were inde-
pendent factors affecting the OS. We entered these three
factors into the multivariate analysis, and found that
volume reduction surgery (HR = 0.309; 95 % CI = 0.152–
0.615) and postoperative chemotherapy (HR = 0.136;
95 % CI = 0.056–0.353) were influential.
In the subgroup analysis of OS in patients who had
P(+) and/or CY(+) with LN(−)H(−), the resection group
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had a longer survival time, whereas no survival benefit
was obtained from the non-curative resection in LN(+)
or H(+) patients (Table 3). In the subgroup analyses
based on histological classification, in patients with
tubular adenocarcinoma, the resection group showed a
longer survival time. However, patients with other types
of gastric cancer, including poorly differentiated adeno-
carcinoma and signet cell adenocarcinoma, did not ex-
perience a survival benefit from the non-curative
resection. For patients who received chemotherapy after
surgery, the resection group showed a longer survival
time, whereas no survival benefit was obtained for pa-
tients who did not receive postoperative chemotherapy.
We combined the subgroup analyses to investigate the
interaction of LN(+) or H(+) and with non-tubular
adenocarcinoma (Table 4). The patients who had CY(+)
and/or P(+) with LN(−) P(−) showed a survival benefit
despite the histological type, while patients who had
LN(+) or H(+) showed no survival benefit independent
of the histological type.
Table 1 Comparison of demographic and other characteristics between the gastric resection and no-resection groups. There were
statistically significant differences in operation time, estimated amount of bleeding, initial oral intake, and complication rate
Characteristics All (n = 72) Gastric resection group (n = 44) No-resection group (n = 28) p value
Age 68 (22–87) 68 (32–87) 68 (22–87) 0.218
Gender (male to female ratio) 50:22 28:16 22:6 0.180
PS ≥ 2 8 (11.1 %) 5 (11.4 %) 3 (10.8 %) 0.931
ASA-PS ≥2 43 (59.7 %) 26 (59.1 %) 17 (60.8 %) 0.891
Residual stomach cancer 3 (41.7 %) 2/44 (4.5 %) 1/28 (3.6 %) 0.840
Incurable factor (P:CY:LN:H (include overlap)) 38:38:11:4 21:24:7:2 17:14:4:2 –
Histological classifications(por:sig:tub:others) 36:12:21:3 20:6:16:2 16:6:5:1 0.371
Resection of other organs Liver;4, T/C;3 sp;1, GB;7 Liver;4, T/C;2, spleen;1, GB;6 T/C 2; GB;1 –
Operation time (min) 225 (49–566) 254 (164–498) 115 (49–566) <0.01
Estimated amount of bleeding (ml) 120 (0–1464) 266 (0–1457) 20 (0–1464) <0.01
Initial oral intake (POD) 5 (1–8) 6 (2–7), impossible 1 4 (1–8) <0.01
Complications rate (Clavian-Dindo≥ II) 14 (19.4 %) 12 (27.3 %) (II:5, IIIa:6, V:1) 2 (7.1 %) (II:2) 0.036
Postoperative chemotherapy 56 (77.8 %) 35 (79.5 %) 21 (75.0 %) 0.651
Obstruction symptoms 4 (5.6 %) 2 (4.5 %) 2 (7.1 %) 0.639
PS performance status, ASA-PS ASA physical status, por poorly differentiated adenocarcinoma, sig signet cell adenocarcinoma, tub tubular adenocarcinoma,
POD postoperative days, T/C transverse colon, GB gallbladder



























Fig. 1 In the survival analysis (log-rank test), the median survival time (MST) in the resection group and no-resection groups were 1.9 and 0.9 years,
respectively (p = 0.014). Overall survival (log-rank test)
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We performed Fisher’s exact test to examine the rela-
tionship between the presence of LN(+) or H(+) and the
rate of postoperative chemotherapy. In patients with
LN(+) or H(+), postoperative chemotherapy was per-
formed in 14 and not performed in 2. Meanwhile, post-
operative chemotherapy was performed in 42 patients
and not performed in 13 patients who have LN(−)H(−).
Postoperative chemotherapy was performed regardless
of the existence of LN(+) or H(+) (p = 0.501).
Discussion
Gastric cancer is the second leading cause of cancer-
related deaths in Japan [3]. Complete R0 resection and
negative lymph nodes are the most important factors for
long-term survival. However, various factors render gas-
tric cancer incurable in many patients. Radical excision
(R0 surgery) is impossible in stage IV advanced gastric
cancer, and the treatment of the patient mainly consists
of chemotherapy, palliative surgery, and symptomatic
treatment [4–6]. The prognosis of advanced gastric can-
cer remains poor despite improvements in its treatment
over the last two decades [7], and the expected survival
period of untreated stage IV gastric cancer was reported
to be 3–5 months [1]. Systemic chemotherapy alone has
been reported to extend the OS by up to 9–11 months
[2]. In addition, the molecular targeting agent trastuzu-
mab has also been reported to prolong OS by 11–
14 months; however, the survival benefit of chemother-
apy alone is limited.
The efficacy and indication of palliative surgery for in-
curable gastric cancer remain controversial [8–10]. Al-
though some studies have demonstrated a survival benefit
of non-curative gastrectomy [11, 12], most retrospective
analyses show no survival benefit and recommend that
palliative gastrectomy be performed if patients have
tumor-related symptoms [13–16]. Although retrospective
studies by nature have inherent selection bias and some
confusion exists regarding their interpretation, the indica-
tion of non-curative gastric resection for stage IV gastric
cancer is currently strictly restricted [17].
Two randomized, controlled trials have been con-
ducted that may provide further insight into the survival
Table 2 Cox proportional hazard model based on the uni- and
multivariate analyses to determine the independent factors for
the overall survival (OS). For the univariate analysis, we selected
tubular adenocarcinoma, gastric resection, and postoperative
chemotherapy as independent factors affecting the OS. Similarly,
for the multivariate analysis, we selected volume reduction and
postoperative chemotherapy as independent factors associated
with OS
Univariate analysis Hazard ratio 95 % CI p value
Male 0.976 0.518–1.944 0.941
Age≥ 68 1.070 0.584–1.954 0.825
PS≥ 2 2.329 0.990–4.881 0.053
ASA-PS≥ 2 1.156 0.623–2.179 0.648
Tubular adenocarcinoma 0.483 0.231–0.935 0.030
P(+) and/or CY (+) 0.886 0.448–1.913 0.744
LN(+) or H(+) 0.970 0.476–1.851 0.928
Non-curative gastric resection 0.326 0.172–0.614 <0.01
Complications (Clavian-Dindo ≥ 2) 1.820 0.832–3.679 0.127
Postoperative chemotherapy 0.260 0.120–0.626 0.004
Multivariate analysis Hazard ratio 95 % CI p value
Tubular adenocarcinoma 0.531 0.233–1.130 0.102
Non-curative gastric resection 0.309 0.152–0.615 <0.01
Postoperative chemotherapy 0.136 0.056–0.353 <0.01
PS performance status, ASA-PS ASA physical status
Table 3 Summary of the results of the survival analysis (log-rank test). Overall, the gastric resection group showed a longer survival
time. However, gastric resection provided no survival benefit for patients who have distant lymph node or liver metastasis,
non-tubular adenocarcinoma, or did not undergo postoperative chemotherapy






• Entirely 1.9 (n = 43) 0.9 (n = 28) <0.01
• Incurable factors
P(+) and/or CY (+), LN(−)H(−) 2.6 (n = 34) 0.8 (n = 21) <0.01
P(−)CY(−), LN (+) or H (+) 1.7 (n = 7) 1.6 (n = 5) 0.527
• Histological classifications
Tubular adenocarcinoma 1.9 (n = 16) 0.6 (n = 10) 0.042
Poorly differentiated adenocarcinoma 2.6 (n = 28) 1.0 (n = 18) 0.318
Signet cell adenocarcinoma 1.4 (n = 5) 0.8 (n = 6) 0.070
• Postoperative chemotherapy
Chemotherapy (+) 3.0 (n = 36) 0.9 (n = 21) <0.01
Chemotherapy (−) 0.7 (n = 8) 0.2 (n = 7) 0.589
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benefits of non-curative gastrectomy. Rudloff and col-
leagues reported the results of the GYMSSA trial and
concluded that complete cytoreductive surgery com-
bined with hyperthermic intraperitoneal chemotherapy
and systemic chemotherapy may improve OS more than
systemic chemotherapy alone [18]. A prospective ran-
domized trial (REGATTA; JCOG0705/KGCA01) was ini-
tiated in three Asian countries in 2008 and was designed
to compare gastrectomy plus chemotherapy to chemo-
therapy alone in advanced gastric cancer with a single
non-curative factor [19]. Currently, no large-scale ran-
domized controlled trial has denied the benefit of non-
curative gastric resection for stage IV gastric cancer,
making it important to select patients who may experi-
ence a survival benefit of this procedure.
Tokunaga and coworkers did not find a survival bene-
fit of palliative gastrectomy in patients with peritoneal
metastasis [16]. Chen et al. reported that palliative gas-
trectomy combined with hepatectomy improved the OS
of patients who had stage IV gastric cancer with liver
metastases [13]. Our study demonstrated that the inde-
pendent factors related to OS were non-curative gastric
resection and postoperative chemotherapy. Although the
OS of the gastric resection group was significantly lon-
ger than the no-resection group, this result was not sur-
prising because cases in the no-resection group had
more severe invasion to the other organs. In this study,
gastric resection was performed when invasion to the
other organs was minimal and the procedure was pos-
sible. Therefore, the resection group had the potential
for longer survival than the no-resection group, and our
result may reflect the impact of invasion to other organs,
i.e., the existence of resectability, rather than the effect
of the procedure itself. In subgroup analyses, although
we found longer survival times in patients whose incur-
able factors were P(+) and/or CY(+), it remains un-
known how the resection itself influenced the survival
time. Meanwhile, we found no prognostic difference be-
tween the gastric resection and no-resection groups in
cases whose incurable factors were LN(+) or H(+) and in
patients who did not receive postoperative chemo-
therapy. It is worth noting that patients with LN(+)
or H(+) and those who did not undergo postoperative
chemotherapy received no survival benefit from non-
curative gastric resection even though the OS of the
gastric resection group was significantly longer. Al-
though we suspected that non-tubular adenocarcinoma
was also the independent risk factor that opposes the sur-
gical resection, we considered that LN(+) or H(+) more
strongly influenced to OS.
This study has some limitations. As in all retrospective
investigations, selection bias is present in this study. The
different surgeons judged whether non-curative gastric
resection was possible or not. To clarify the veridical ef-
ficacy of non-curative gastric resection, we should com-
pare patients with and without gastric resection among
patients in whom gastric resection is possible. Another
limitation is the non-standardized nature of the chemo-
therapy regimen, which differed over time and some-
times by case. In addition, we could not evaluate the
impact of HER-2 positive or not, although it affects the
prognosis, and involved also in the selection of treat-
ment [4, 5]. Quality of life is one of the most important
endpoints for individuals with advanced gastric cancer
[20]; however, we could not measure it prospectively.
Further studies involving more standardized and pro-
spective analyses are needed.
Conclusions
In conclusion, we believe that this study provides one in-
dicator to determine whether non-curative gastric resec-
tion should be performed when stage IV gastric cancer
is diagnosed during the operation. Non-curative gastric
resection for stage IV gastric cancer may provide a sur-
vival benefit for patients whose incurable factors are
P(+) or CY(+) and postoperative chemotherapy is per-
formed. Meanwhile, there was no survival benefit for
patients who have LN(+) or H(+) and who did not
undergo postoperative chemotherapy; therefore, it
should be strictly restricted in these circumstances.
Ethics
This study was approved by the ethical committee of
Asahi General Hospital and the reference number was
2014091620. Informed consent and consent to publish
were obtained from the patients or their families.
Table 4 Subgroup analysis of the overall survival. Despite the histological type, a survival benefit from gastric resection was observed in
patients who did not have distant lymph node or liver metastasis
Condition Tubular adenocarcinoma Non-tubular adenocarcinoma (por, sig, others)
P(+) and/or CY(+), LN(−)H(−) Resection (n = 9) MST;
3.1 years
No-resection (n = 3) MST;
0.6 years
Resection (n = 25) MST;
1.4 years
No-resection (n = 18) MST;
0.8 years
p < 0.01 p = 0.034
P(−)CY(−), LN(+) or H(+) Resection (n = 5) MST;
1.7 years
No-resection (n = 2) MST;
1.2 years
Resection (n = 1) survival time;
1.0 years
No-resection (n = 3) MST;
1.6 years
p = 0.819 –
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